Research indicates that both Dovitinib and Lucitanib exhibit significant inhibitory effects specifically in breast cancer patients with FGFR1 amplification, while sparing normal cells from adverse effects [46,47]. The gene discussed is FGFR1; the disease is breast carcinoma.